CX Institutional’s Fulgent Genetics FLGT Stock Holding History

CX Institutional’s Portfolio FLGT Stock Details FLGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-19,808	Closed	-$755K	–	524
2022 Q3	$755K	Buy	19,808 +7,365	+59%	+$369K	0.05%	301
2022 Q2	$678K	Buy	+12,443	New	+$684K	0.05%	277

Other funds holding FLGT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

CX Institutional's FLGT Position: Q4 2022 in Review

CX Institutional sold out of Fulgent Genetics (FLGT) in Q4 2022, closing a stake of 19,808 shares — an estimated $755K sold.

CX Institutional first reported a position in FLGT in Q2 2022 and held it in 2 quarters. The position peaked at $755K in Q3 2022. 224 funds tracked by Wall St. Rank hold FLGT as of Q4 2022.

CX Institutional reported no remaining Fulgent Genetics position as of Q4 2022 after selling out during the quarter.
CX Institutional sold 19,808 Fulgent Genetics shares in Q4 2022, an estimated $755K.
CX Institutional first reported a position in Fulgent Genetics in Q2 2022 and held it in 2 quarters.
CX Institutional's Fulgent Genetics position peaked at $755K in Q3 2022.
224 funds tracked by Wall St. Rank held Fulgent Genetics as of Q4 2022.

Based on CX Institutional's 13F filing for Q4 2022, filed 3 Feb 2023.